1-3 of 3
Ye Yuan
Close
Sort by
Journal Articles

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

Clinical Trials & Observations
Jianxiang Wang, Zhi-Xiang Shen, Giuseppe Saglio, Jie Jin, He Huang, Yu Hu, Xin Du, Jianyong Li, Fanyi Meng, Huanling Zhu, Jianda Hu, Jianmin Wang, Ming Hou, Sabine Hertle, Hans D. Menssen, Christine-Elke Ortmann, Catherine Tribouley, Ye Yuan, Michele Baccarani, Xiaojun Huang
Journal: Blood
Blood (2015) 125 (18): 2771–2778.
https://doi.org/10.1182/blood-2014-09-601674
Published: 2015
Journal Articles

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

Xiaojun Huang, Jianxiang Wang, MD, Michele Baccarani, MD, Svetlana Jevtic, Christine-Elke Ortmann, Ye Yuan, Hans D. Menssen, MD, PhD, Giuseppe Saglio, Zhi-Xiang Shen, MD
Journal: Blood
Blood (2013) 122 (21): 1497.
https://doi.org/10.1182/blood.V122.21.1497.1497
Published: 2013
Journal Articles

SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment

Bo Huang, Zhang Lei, Gui-Mei Zhang, Dong Li, Chuanwang Song, Bo Li, Yanyan Liu, Ye Yuan, Jay Unkeless, Huabao Xiong, Zuo-Hua Feng
Journal: Blood
Blood (2008) 112 (4): 1269–1279.
https://doi.org/10.1182/blood-2008-03-147033
Published: 2008
Includes: Supplemental data